Skip to content

The study of press needle on immunity function among breast cancer patients after radical mastectomy

The study of press needle on immunity function among breast cancer patients after radical mastectomy

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000040100
Enrollment
Unknown
Registered
2020-11-21
Start date
2020-11-01
Completion date
Unknown
Last updated
2021-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

control group:Sham press needle

Sponsors

Affiliated Hospital of Chengdu University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Patients with breast cancer diagnosed by pathology. 2.Patients who have undergone radical mastectomy. 3.Did not receive radiotherapy, chemotherapy or any other drugs that affect immune function before surgery. 4.No other tumors, acute or chronic inflammations, blood system diseases and autoimmune diseases. 5.Age 18–80 years, female gender. 6.ECOG PS of 0-2, life expectancy >= 3 months. 7.With normal bone marrow, heart, liver and kidney functions. 8.Ability to understand and the willingness to sign a written informed consent document, capable of providing responses during outcome measurement.

Exclusion criteria

Exclusion criteria: 1.History of other malignant tumors within 5 years. 2.Patients with active autoimmune disease. 3.Active infection, including active tuberculosis infection. 4.Severe infection after surgery. 5.Radiotherapy, chemotherapy, acupuncture, press needle or drugs that affect immune function received within the past 4 weeks. 6.Life expectancy < 3 months. 7.Comorbidities such as serious heart, kidney, or liver diseases. 8.Pregnancy or currently lactating(including patients of reproductive age who do not want to use contraception); severe mental disorders such as cognitive impairment. 9.Refusal to accept press needle. 10.Participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
The proportion of (CD8 +) T cells in peripheral blood;The proportion of (CD4 +) T cells in peripheral blood;The proportion of (CD3 +) T cells in peripheral blood;The proportion of (CD4 + / CD8 +) T cells in peripheral blood;

Secondary

MeasureTime frame
KPS score;EORTC QLQ-C30 score;

Countries

China

Contacts

Public ContactTao Liu

Affiliated Hospital of Chengdu University of Traditional Chinese Medicine

20137312@qq.com+86 13540734080

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 9, 2026